Sangamo Therapeutics reports progress in gene therapies

Gene therapy for sickle cell disease | American Society of Hematology

Available results from a small number of patients, some with relatively short follow-up, are promising as a potentially curative strategy, with ...

New data boost Pfizer, Sangamo hemophilia A gene therapy

In April, Sangamo suggested the gene therapy may live up to that promise by revealing data from the first two patients to receive the highest ...

Gene therapy clinical trials worldwide to 2023—an update - Ginn

In October 2016, a patient with lung cancer became the first to be treated with CRISPR/Cas9 modified T cells in a Chinese clinical trial ( ...

StockWatch: Phase III Data for Pfizer-Partnered Hemophilia A Gene ...

Sangamo stock soared this week after it joined Pfizer to report positive Phase III data for their hemophilia A gene therapy candidate.

Sangamo Reaches Accord With FDA on Plans for Accelerated ...

Sangamo Reaches Accord With FDA on Plans for Accelerated Approval Pathway for Fabry Disease Gene Therapy ST-920 · CGTLive®'s Weekly Rewind – ...

Form 10-K for Sangamo Therapeutics INC filed 02/23/2023

Annual progress reports detailing ... research, development and commercialization of gene regulation therapies for the treatment of neurological diseases.

Sangamo pitches gene therapy progress, yet investors stay skeptical

Rather than edit the DNA of target cells outside of the body, Sangamo's therapy does its work inside a patient. And, in contrast to CRISPR-based ...

Gene therapy for sickle cell disease: moving from the bench to the ...

Advances in genomic sequencing have increased the understanding of Hb regulation, and discoveries of molecular tools for genome modification of hematopoietic ...

The translational gap for gene therapies in low- and middle-income ...

In April 2024, there were approximately 1116 open gene therapy clinical trials (including those using CAR T cells) and RNA-based therapy ...

Gene therapy for hemophilia, a clinical viewpoint - ScienceDirect

It can also be considered safe with careful practice on selected patients. In its current form, gene therapy will not replace all hemophilia treatments.

2018 - Alliance for Regenerative Medicine

financial progress of 900+ therapeutic developers worldwide. ... Kite Pharma signs $150M agreement with Sangamo Therapeutics for gene-modified cell therapies for ...

Pfizer Marks Phase III Success in Hemophilia A, then Layoffs after ...

Pfizer marked a success, and a setback, in its ongoing effort to develop gene therapies. The company joined Sangamo Therapeutics to report positive Phase III ...

Sangamo gene therapy shows promise in beta thalassemia study

Preliminary results from Sangamo Therapeutics' THALES trial of ST-400 have demonstrated favourable profile of the gene therapy in treating ...

Genentech-Sangamo deal to advance neurodegenerative treatments

Genentech, a member of the Roche Group, and Sangamo Therapeutics have agreed to work together to develop intravenous genomic medicines for neurodegenerative ...

Sangamo Reports Pfizer's Positive Phase 3 Hemophilia A Gene ...

Giroctocogene fitelparvovec has received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. FDA, along with Orphan ...

Sangamo shares jump as FDA clears faster gene therapy pathway

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and Drug Administration has granted the ...

Genentech and Sangamo to develop new therapies

Sangamo Therapeutics has signed an agreement with Genentech for the development of genomic medicines to treat neurodegenerative diseases.

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo is developing epigenetic regulation therapies to treat serious neurological diseases and novel proprietary AAV capsids designed to ...

Genomic Medicine Clinical Trials - Sangamo Therapeutics, Inc.

We are conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of ST-920 gene therapy in Fabry disease. Program Details · Clinical Trial ...

A new age of precision gene therapy - The Lancet

This Therapeutic Review aims to explain how progress in genome editing technologies offers the possibility to expand both therapeutic options ...